We found that stroke patients had elevated plasma soluble CD137L levels and increased CD137L expression in monocytes, suggesting a dysregulation of CD137/CD137L signaling in the early stage of this disorder.15 To verify these findings, it is necessary to conduct further studies on CD137 expression and explore its roles in the pathogenesis of ischemic stroke. The gene discussed is TNFRSF9; the disease is stroke disorder.